KPV
200 mcg · Daily
Evidence
- Human Studies
- 1
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — almost entirely animal-model evidence, minimal human data
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), studied mainly in animal models of inflammatory bowel disease and skin inflammation for anti-inflammatory effects that appear largely independent of the pigmentation effects of full-length melanocortin peptides.
Common Protocols
- 200 mcg subcutaneous daily, or oral capsule forms sold for gut-focused use — human dosing for either route is not established by clinical trials
Side Effects
- Limited systematic human safety data
- Injection site irritation (injectable form)
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution (injectable); oral capsules per product label
Research Links
Anti-inflammatory tripeptide fragment of alpha-MSH; oral and injectable forms both used informally